FloridaTaper

Category: Iatrogenic Injury

  • Prescribed Dependence Is Not Addiction: Why Language Matters in Benzodiazepine Deprescribing

    Prescribed Dependence Is Not Addiction: Why Language Matters in Benzodiazepine Deprescribing

    One of the most damaging misunderstandings in modern medicine is the assumption that anyone who depends on a medication must be an addict. For people who take benzodiazepines exactly as prescribed, this assumption causes real harm. It changes how doctors treat them, how families view them, and how patients see themselves.

    Words shape care. When a patient is labeled an addict, the treatment plan shifts toward addiction recovery models that do not fit the problem. Getting the language right is the first step toward getting the treatment right.

    The Difference Between Dependence and Addiction

    Physical dependence is a normal, expected response of the body to a medication taken over time. When a person takes a benzodiazepine for weeks or months, the nervous system adapts to its presence. Stopping suddenly produces withdrawal because the body has come to rely on the drug to function.

    Addiction is a different condition entirely. It involves compulsive use despite harm, loss of control, and behavior organized around obtaining and using a substance. A person can be physically dependent on a medication without any of these features.

    Most patients prescribed benzodiazepines fall into the first category, not the second. They took the medication their doctor gave them, followed the instructions, and developed dependence as a predictable result. They are not chasing a high or losing control of their lives around a drug.

    Confusing these two conditions leads to the wrong response. Dependence calls for a gradual medical taper. Addiction may call for additional support, but even then, the physical dependence still needs to be treated medically rather than dismissed.

    How Prescribed Dependence Happens

    Benzodiazepines are often prescribed for anxiety, panic, or sleep. They work quickly, which makes them appealing for short-term relief. The problem is that they are frequently prescribed for far longer than the brief periods for which they were studied.

    Over months of daily use, the brain reduces the number and sensitivity of its calming receptors. This process, called receptor downregulation, is the biological root of dependence. It happens silently, without the patient doing anything wrong.

    By the time a patient or doctor recognizes the problem, the dependence is already established. The patient cannot simply stop, because the nervous system no longer regulates itself the way it once did. This is a medical situation created by treatment, not a character flaw.

    Recognizing this pattern is central to the work of physicians like Mark Leeds, D.O., who focuses on benzodiazepine and psychiatric medication tapering. The starting point is understanding how the dependence formed in the first place.

    Why the Word Addiction Causes Harm

    When a dependent patient is called an addict, the consequences are not just emotional. The label changes the care they receive and often makes their situation worse.

    Patients may be pushed toward rapid detox programs or twelve-step meetings that were designed for substance use disorders. These settings rarely understand slow tapering and often expect patients to be free of the medication within days or weeks. For someone whose nervous system needs many months to adjust, this approach can be devastating.

    The label also affects how patients are treated when they seek help. A person flagged as drug-seeking may have their symptoms dismissed or their prescriptions cut without a plan. This can force a dangerous abrupt stop.

    Just as damaging is the shame the word creates. Patients begin to doubt themselves, hide their situation, and avoid asking for help. Accurate language removes that shame and opens the door to proper care.

    Iatrogenic Injury: Naming It Correctly

    A more accurate term for prescribed dependence is iatrogenic injury, which means harm that results from medical treatment. The patient did not seek out a drug for misuse. They followed a prescription and were injured as a result.

    This framing matters because it places responsibility where it belongs and removes the burden of blame from the patient. It also points toward the right kind of help, which is careful medical management rather than addiction programming.

    Naming the injury accurately does not mean blaming any single person. It means acknowledging that long-term prescribing without an exit plan can cause harm. That acknowledgment is what allows real treatment to begin.

    For many patients, hearing their condition described as an injury rather than an addiction is a turning point. It validates their experience and reframes recovery as healing from harm, not overcoming a moral weakness.

    What Correct Language Changes in Treatment

    When dependence is recognized for what it is, the treatment plan follows logically. The goal becomes a slow, individualized taper that respects how the patient’s body responds. There is no race to a finish line.

    Crossover tapers to a longer-acting benzodiazepine, guided by the principles in the Ashton Manual, are often used to make the process smoother. Liquid compound formulations allow very small reductions when needed. The pace adapts to the patient rather than to an insurance timeline.

    The patient becomes a partner in the plan, not a subject to be managed. They retain control over the speed and direction of their taper. This partnership is the opposite of the control-based approach common in addiction settings.

    Correct language also changes the emotional tone of care. A patient treated as an injured person deserving help heals in a very different environment than one treated as an addict to be corrected.

    Talking to Doctors and Family About Dependence

    Patients can advocate for themselves by using precise words. Explaining that they are physically dependent on a prescribed medication, not addicted, helps reframe the conversation with a skeptical provider.

    The updated benzodiazepine labeling now formally recognizes physical dependence, withdrawal reactions, and the need for gradual dose reduction. Pointing to this official recognition can help patients be taken seriously by dismissive physicians.

    Family members benefit from the same clarity. When loved ones understand that a patient is recovering from a medical injury, they are less likely to push for quick fixes like detox. They can offer steady support instead.

    This shared understanding reduces conflict at home and helps everyone pull in the same direction. The patient feels supported rather than judged, which itself supports recovery.

    Why the Confusion Persists in Medicine

    If the difference between dependence and addiction is so clear, it is fair to ask why so many clinicians blur it. Part of the answer lies in how medical training has historically grouped these concepts together. For decades, the language of substance use dominated discussions of any drug the body comes to rely on.

    Benzodiazepines sit in an awkward space. They are controlled substances with real potential for misuse, which makes some prescribers quick to view any dependence through the lens of addiction. This caution, while understandable, often misses the much larger group of patients who simply followed their prescriptions.

    There is also a practical pressure at work. It is faster to apply a familiar label than to take the time to understand a patient’s individual history. A busy clinician may reach for the addiction framework because it is the one most readily available.

    The result is that many dependent patients are sorted into a category that does not describe them. Changing this requires both better education and patients who can clearly explain their situation.

    Recognizing why the confusion persists helps patients approach skeptical providers with less frustration. The mislabeling is often a reflex rather than a considered judgment, and a calm, accurate explanation can sometimes shift it.

    Healing the Self-Image After the Label

    Being treated as an addict leaves marks that go beyond medical care. Many patients internalize the label and begin to see themselves through it, carrying shame that does not belong to them.

    Undoing this takes time and often requires actively rejecting the false framing. Patients benefit from reminding themselves that they developed a medical condition by following medical advice. They did nothing to be ashamed of.

    Connecting with others who understand prescribed dependence can also help. Hearing that countless people share the same experience reduces the isolation that the addict label creates.

    Working with a physician who treats the patient as an injured person, not a wrongdoer, reinforces a healthier self-image. The tone of care shapes how a patient comes to see their own situation.

    A Foundation for Better Care

    The distinction between dependence and addiction is not a matter of semantics. It determines whether a patient receives a careful taper or a harmful crash, validation or dismissal, partnership or control.

    Getting the language right protects patients from inappropriate treatment and restores their dignity. It reframes a difficult experience as a medical condition that can be addressed with the right approach.

    For anyone navigating benzodiazepine deprescribing, insisting on accurate language is a meaningful act of self-advocacy. It is the foundation on which safe, respectful, and effective tapering is built.

  • Pharmacy Nightmares: When Pharmacists Refuse to Fill Your Tapering Prescription

    Pharmacy Nightmares: When Pharmacists Refuse to Fill Your Tapering Prescription

    One of the most frustrating obstacles in modern benzodiazepine tapering has nothing to do with the medication itself, the patient’s nervous system, or the prescriber’s protocol. It is the increasingly common experience of arriving at a pharmacy with a valid prescription and being told the medication cannot be filled. The pharmacist may say they are out of stock, that their supplier cannot provide the medication, that they are not comfortable filling the prescription, or simply that the pharmacy will not be filling it. The patient leaves empty-handed, with a taper that depends on continuity, and a problem that has to be solved before the next dose is due.

    This pattern has become so common in the past several years that benzodiazepine patients now routinely build pharmacy strategy into their tapering plans. The problem is not going away, and understanding what is driving it and how to navigate it is now part of being a tapering patient.

    What Is Driving the Refusals

    Pharmacy refusals on benzodiazepine prescriptions have multiple drivers, and most of them have nothing to do with the individual patient.

    Regulatory pressure on controlled substances. Pharmacies face increasing scrutiny over how they handle Schedule IV medications, including benzodiazepines. The same enforcement environment that has changed opioid prescribing has begun to extend to benzodiazepines, and pharmacists who feel exposed to liability are responding by being more conservative about which prescriptions they fill.

    Wholesaler limits on dispensing. Pharmaceutical wholesalers track the volume of controlled substances each pharmacy orders, and they impose limits that can produce supply problems even when the underlying prescriptions are entirely legitimate. A pharmacy that has reached a threshold for a particular medication may be unable to order more until the next reporting period, even when patients with valid prescriptions are waiting.

    Pharmacist discretion. Pharmacists in the United States have legal latitude to refuse to fill prescriptions they have concerns about. The criteria for that discretion are not always clearly defined, and a pharmacist who is uncertain about a prescription, the prescriber, or the patient may decline to fill rather than risk a problem. Long-term benzodiazepine prescriptions, slow tapers using compounded liquid formulations, and prescriptions from physicians the pharmacist does not recognize all increase the chance of refusal.

    Pharmacy chain policies. Some large chains have internal policies about quantity limits, refill timing, and acceptable prescriber relationships that go beyond what the law requires. A patient who has filled prescriptions at the same pharmacy for years can encounter a sudden policy change that makes their established treatment difficult to continue.

    Insurance and prior authorization friction. Even when the pharmacy is willing to fill the prescription, insurance complications can produce delays that look and feel like refusals. Prior authorization requirements, formulary changes, and step therapy rules add friction that benzodiazepine patients do not have time to absorb during a careful taper.

    Common Scenarios

    Patients describe several recurring experiences.

    Outright refusal. The pharmacy declines to fill the prescription. Sometimes a reason is given. Sometimes not. The patient is told to find another pharmacy. The hand-off, when there is one, is rarely seamless.

    Partial fills. The pharmacy fills a smaller quantity than prescribed, often citing supply or policy. The patient now has to come back for the remainder, and there is no guarantee the rest will be available when they do.

    Indefinite delays. The pharmacy says they will fill the prescription but cannot do so today. Sometimes tomorrow. Sometimes next week. For a patient on a careful taper schedule, indefinite is not a workable response.

    Non-standard formulations. Compounded liquid benzodiazepines, low-dose preparations, and unusual dosing schedules are particularly likely to encounter pharmacy difficulty. Most pharmacies do not compound, and the ones that do may not have a working relationship with the patient’s prescriber.

    Refusal to accept transfers. A patient who has been refused at one pharmacy and tries to transfer to another sometimes finds that the new pharmacy will not accept a transfer of a controlled substance prescription, particularly when the script appears to have been declined elsewhere.

    The Impact on Tapering Patients

    For a patient managing a slow benzodiazepine taper, a pharmacy refusal is more disruptive than it would be for most other medications. Continuity matters in tapering. A planned reduction at the end of the month assumes the previous dose has been available consistently. Missing days, switching formulations mid-taper, or jumping doses because the medication was not available creates instability that can take weeks to recover from.

    Patients describe being placed in an impossible position. Their prescriber has set a careful schedule. The pharmacy has interrupted it. The patient is now choosing between filling at a different pharmacy under unfamiliar conditions, going without medication, or contacting the prescriber for a workaround. Each option costs time and energy the patient does not have to spare.

    The downstream consequences include increased anxiety, sleep disruption from worry about the next refill, additional symptoms from missed doses, and erosion of the patient’s confidence that the system supporting their taper will continue to do so. Some patients describe these pharmacy episodes as more destabilizing than the dose reductions themselves.

    What Patients Can Do

    Several strategies reduce the chance of being caught by a refusal at a critical moment.

    Establish a relationship with a specific pharmacy. Patients who fill consistently at a single pharmacy, build relationships with the pharmacists, and become familiar names tend to encounter fewer surprise refusals than patients who move from pharmacy to pharmacy. The pharmacist who knows the patient and the prescriber is more likely to fill without difficulty.

    Identify a backup pharmacy in advance. A second pharmacy that has filled a prescription at least once, where the patient is also a known customer, provides a fallback. Identifying this backup before it is needed avoids scrambling under pressure.

    Refill earlier when possible. If insurance and prescriber rules allow, filling a few days before the previous supply runs out provides margin. A delay or refusal on a day when there are still pills in the bottle is much less stressful than a delay on the day of the last dose.

    Carry written documentation. A patient who has a letter from their prescriber describing the diagnosis, the tapering plan, and the medical necessity of the medication has a tool that can sometimes resolve a pharmacist’s concerns. Not every pharmacist will accept the letter as decisive, but it shifts the conversation.

    Communicate with the prescriber promptly when refusals occur. The prescriber may be able to call the pharmacy directly, redirect the prescription to a different pharmacy, or adjust the prescription to address whatever concern is being raised. A patient who waits days before contacting the prescriber is in a worse position than one who reports the refusal immediately.

    Understand the difference between refusal and supply. A genuine supply issue is different from a pharmacist’s refusal, and the workaround is different. A patient who can identify which is happening can respond appropriately rather than spending energy on the wrong intervention.

    Compounding Pharmacies as an Alternative

    For patients who need liquid formulations, very low doses, or non-standard concentrations, a compounding pharmacy may sidestep the problem entirely. Compounding pharmacies that work with benzodiazepine tapers do not face the same supply and policy pressures as retail chain pharmacies. They typically build long-term relationships with patients on tapers, understand the importance of continuity, and have processes for handling slow reductions over time.

    The downside is that compounding pharmacies are not on every corner, often require shipping arrangements, and may cost more out of pocket than retail. The upside is reliability for patients who have been burned by retail refusals. For a patient who is finding their taper repeatedly disrupted by pharmacy issues, the move to a compounding pharmacy is sometimes the single most stabilizing change they can make.

    The Clinical View

    Dr. Leeds works with patients whose tapers have been disrupted by pharmacy refusals, and he treats this category of disruption as a clinical problem rather than a logistical one. A patient whose taper has been thrown off by a pharmacy issue is in just as much need of clinical support as a patient whose taper has been thrown off by a too-large dose reduction. The destabilization is real either way.

    Building a stable pharmacy relationship is part of building a stable taper. For some patients, this means a single retail pharmacy that knows them well. For others, it means a compounding pharmacy with a long-term arrangement. For nearly all of them, it means having a backup plan in place before it is needed.

    The pharmacy environment is unlikely to become easier for benzodiazepine patients in the near future. Tapering successfully in this environment requires planning, patience, and a willingness to advocate for one’s own care. The patients who navigate this well are the ones who treat pharmacy strategy as part of their treatment plan rather than as an afterthought.

  • Why the Baker Act Is a Real Danger for Benzo-Injured Patients Seeking ER Help

    Why the Baker Act Is a Real Danger for Benzo-Injured Patients Seeking ER Help

    For most Floridians, the Baker Act is a distant phrase that surfaces occasionally in news coverage. For patients in the middle of a difficult benzodiazepine taper, the Baker Act is something else entirely: a real and immediate danger that can convert a desperate visit to the emergency room into a multi-day involuntary psychiatric hold, with all the medication choices made by clinicians who do not understand what is happening to the patient. The Baker Act exists for legitimate reasons, but the way it interacts with benzodiazepine-related neurological dysfunction creates a catch-22 that every patient and family member should understand before a crisis develops.

    Patients who are deep into a benzodiazepine taper, or who are living with Benzodiazepine-Induced Neurological Dysfunction (BIND), often reach a point of suffering that drives them toward emergency rooms. The hope is straightforward: the symptoms have become unbearable, and somewhere in the medical system there must be help. The reality, in too many cases, is that the emergency room visit becomes the start of a worse problem, not a solution to the original one.

    Why Benzo-Injured Patients End Up in Emergency Rooms

    The trajectory is familiar to anyone who has lived through a difficult taper. A patient is managing through waves and windows, then a wave hits harder than the previous ones. Sleep collapses. Akathisia builds. The patient cannot eat, cannot sit still, cannot think clearly. Family members watch helplessly. After two or three days of this, with no improvement and no obvious next step, someone calls an ambulance or drives the patient to the emergency room.

    The presentation is striking from the outside. The patient is pacing or unable to remain still. They describe internal sensations that they cannot quite explain. They may say they cannot live like this. They may say they want it to stop. They may be unable to keep a coherent train of thought together. Their physical state is one of obvious crisis.

    From the perspective of the emergency room clinician, who has seen thousands of patients and has perhaps seven minutes to make a triage decision, this presentation maps onto a familiar template: a person in acute psychiatric distress who is verbalizing thoughts of self-harm or hopelessness, who appears agitated, and who may be a danger to themselves. That template, in Florida, leads directly to the Baker Act.

    The Baker Act and How It Gets Triggered

    The Baker Act allows for involuntary examination of a person who appears to have a mental illness and who, because of that mental illness, has refused voluntary examination, or who is unable to determine whether examination is necessary, and who without care is likely to suffer from neglect or to inflict serious bodily harm on themselves or others. The criteria sound narrow on paper. In practice, the bar is lower than patients expect, and the language a patient uses in an emergency room can trigger the determination quickly.

    A patient who says, “I cannot live like this,” may be expressing the truth of their suffering without meaning that they are planning self-harm. To an emergency room evaluator with a full waiting room and a low threshold for liability, the statement reads as suicidal ideation. The Baker Act paperwork begins. The patient is now legally held for examination, typically for up to 72 hours, and the medication decisions are about to be made by people who do not know the patient’s history.

    This is where the catastrophe usually starts.

    What Happens Once a Patient Is Held

    The default treatment approach for an agitated patient in a Baker Act setting is sedation, often with antipsychotics, additional benzodiazepines, or both. None of these medications addresses what is actually happening in a benzodiazepine-injured nervous system, and several of them make the situation considerably worse.

    Antipsychotics carry a risk of producing or worsening akathisia. A patient who is in withdrawal-related akathisia and is given an antipsychotic may emerge from the hold with two overlapping akathisias from two different mechanisms. That second akathisia will not begin to resolve until the antipsychotic is fully out of the system, which may take weeks.

    Benzodiazepines given during a hold may produce brief stabilization that the patient interprets as relief, then leave the patient with a dose problem to undo afterward. Reinstatement at this stage often requires a careful taper from a higher starting point than where the patient began.

    The hold environment itself, with its bright lights, constant sound, lack of privacy, restricted movement, and complete loss of control over food, sleep, and medication timing, is precisely the wrong environment for a destabilized benzodiazepine-injured nervous system. Patients regularly come out of these holds in worse condition than they entered them.

    The Catch-22

    The dilemma for patients and families is that the moments when emergency help is most needed are also the moments when the emergency system is most likely to cause additional injury. A patient cannot know in advance how a particular emergency room will respond, who will be on duty, or how long the wait will be. The decision to seek help is being made under duress, by people who are themselves exhausted and frightened.

    This is not an argument for never going to the emergency room. There are situations in which immediate medical attention is necessary and life-saving. Acute medical emergencies, suspected serotonin syndrome, severe physical illness, or injury all require emergency care, and the risk of the Baker Act is small compared to the risk of not getting urgent medical treatment. The catch-22 specifically applies to crises that are driven by withdrawal symptoms themselves, where the emergency system is not equipped to recognize the underlying problem.

    What Patients Can Do to Reduce Risk

    The most effective protection is to avoid the emergency room as a first resort for symptom crises that are driven by benzodiazepine withdrawal. This requires a plan made in advance, while the patient is stable.

    Have an established prescriber who understands tapering. A patient with a physician who can be reached during a crisis is in a different position than a patient with no clinical relationship. A phone call to a knowledgeable prescriber can sometimes resolve the question of whether the situation is a wave that needs support or a different problem that needs medical attention.

    Develop a written crisis plan. The plan should describe what symptoms have been part of the patient’s pattern, what has helped during prior waves, what medications are not appropriate, and what family members should do if the patient cannot communicate. Having this document available makes a difference if emergency care does become necessary.

    Bring an advocate. A spouse, family member, or friend who can speak to the clinical context, repeat key information clearly, and stay with the patient during evaluation reduces the chance of misinterpretation. The advocate’s role is not to override the medical team but to ensure that the team has the right information.

    Be careful with language. A patient describing the experience of withdrawal honestly can use phrases that sound, to a clinician without context, like statements of suicidal intent. Saying, “I am suffering and I need help with these symptoms,” conveys the same urgency without triggering the Baker Act framework. Practicing how to describe the experience in advance, with the help of a clinician or family member, is a small step that has real protective value.

    Consider alternatives to emergency rooms. Urgent care centers, telehealth appointments with a specialty prescriber, or scheduled outpatient appointments may serve better than the emergency room for symptom escalations that are not medical emergencies. The emergency room is for emergencies. Withdrawal waves, however severe, are usually not emergencies in the way the system is designed to address.

    The Clinical View

    Dr. Leeds works with benzodiazepine patients who are in or approaching the kind of crisis that drives an emergency room visit. The first goal is always to provide enough clinical support during taper that emergency care does not become necessary. The second goal, when a patient does end up in a difficult moment, is to give them and their family the tools to navigate it without losing control of the medication picture.

    The Baker Act exists to protect people in genuine psychiatric crisis. Used appropriately, it saves lives. The problem for benzodiazepine-injured patients is that their condition does not fit the framework the law is built around. Recognizing that mismatch in advance is what allows patients and families to make informed decisions during the worst hours of a difficult taper.

  • Seroquel for Sleep: When an Antipsychotic Becomes the Problem

    Seroquel for Sleep: When an Antipsychotic Becomes the Problem

    Quetiapine — marketed as Seroquel — is prescribed for sleep more often than for any of the conditions it is actually FDA-approved to treat. It is labeled for schizophrenia, bipolar disorder, and, in combination, major depressive disorder. None of those indications are insomnia. Yet low-dose quetiapine, typically 25 to 100 mg at bedtime, is one of the most common off-label prescriptions in primary care and psychiatry for patients with sleep complaints, particularly patients who are being tapered off benzodiazepines or who have not responded to standard hypnotics.

    The drug is an antipsychotic. That framing matters, and it is regularly lost in the prescribing context. A patient who would reasonably decline an antipsychotic for insomnia if it were presented that way accepts quetiapine because it has been presented as a sleep medication.

    Why Quetiapine Is Prescribed for Sleep

    At low doses, quetiapine’s pharmacology is dominated by histamine H1 receptor antagonism, similar to what is seen with first-generation antihistamines. This produces reliable sedation. Additional activity at 5-HT2A, alpha-1 adrenergic, and muscarinic receptors contributes to the sedating profile at low doses. Dopamine D2 antagonism, the mechanism relevant to the drug’s antipsychotic indications, is modest at 25 to 50 mg and more substantial at higher doses.

    From a prescriber’s perspective, quetiapine is attractive for patients with insomnia who have failed other agents, particularly when the clinician wants to avoid controlled substances. It is not a scheduled drug. It does not produce obvious physical dependence of the kind benzodiazepines produce. It is covered by most insurance and available as a generic.

    The evidence for quetiapine as a hypnotic is thin. A few small trials show subjective improvement in sleep quality; the data are not adequate to recommend the drug for this indication over better-studied alternatives, and the American Academy of Sleep Medicine’s guidelines do not recommend it. The gap between evidence and prescribing practice is one of the larger ones in psychopharmacology.

    What the Side Effect Profile Actually Looks Like

    Low-dose quetiapine is often described as benign. Several features of the profile complicate that description.

    Metabolic effects. Quetiapine produces weight gain, insulin resistance, and lipid changes at doses well below antipsychotic doses. The weight gain is dose-related but not dose-limited; patients on 25 to 50 mg at bedtime can accumulate 10 to 20 pounds over the first year. Glucose and lipid panels should be monitored in any patient on chronic low-dose quetiapine, and in practice they rarely are.

    Orthostatic hypotension. Alpha-1 adrenergic antagonism produces orthostatic effects that are most pronounced early in treatment and in older patients. Nighttime bathroom visits with orthostatic syncope are a recognized cause of falls.

    Akathisia. Even at low doses, quetiapine can produce restlessness and an internal sense of agitation. This is often misread as “worsening anxiety” and produces a dose-increase reflex that makes the problem worse.

    QT prolongation. Quetiapine prolongs the QT interval in a dose-related way. At low doses the effect is modest, but in combination with other QT-prolonging agents (some antidepressants, ondansetron, methadone) the additive risk matters.

    Anticholinergic load. Muscarinic antagonism contributes to dry mouth, constipation, urinary hesitancy, and cognitive symptoms, particularly in older patients. Stacked on other anticholinergics, the total burden is not trivial.

    The Withdrawal Question

    Quetiapine produces physical dependence and withdrawal on discontinuation, particularly after months of continuous use. The most common withdrawal symptoms are rebound insomnia (often worse than the original complaint), rebound anxiety, nausea, sweating, and in some patients akathisia and dyskinetic movements. Protracted symptoms are less well characterized than with benzodiazepines but are reported.

    The rebound insomnia deserves specific attention. Patients who try to discontinue quetiapine abruptly typically experience several nights of nearly no sleep. This is not a return of the original sleep problem — it is a withdrawal phenomenon driven by rebound H1 activity and often accompanies heightened arousal, vivid dreaming when sleep does come, and daytime agitation. The reflexive conclusion is that the patient “needs the medication,” and they resume it. That conclusion is incorrect in most cases; the rebound window usually resolves over one to two weeks on a slow taper.

    Quetiapine During a Benzodiazepine Taper

    A specific and common clinical pattern: a patient tapering a benzodiazepine develops insomnia. The prescriber adds low-dose quetiapine. The insomnia improves initially. The benzodiazepine taper continues. At some point the patient wants to stop the quetiapine as well. They are now facing a second withdrawal that was created by the management of the first.

    This pattern is avoidable if the decision to add quetiapine is made with its exit strategy attached. It is rarely avoided because the exit strategy is rarely defined at the time of the original prescription.

    For patients already in this situation, the typical sequence is to complete the benzodiazepine taper first, allow several months of stabilization, and then taper the quetiapine. Tapering both simultaneously multiplies the withdrawal burden in ways most patients cannot sustain.

    Deprescribing Quetiapine

    The principles are similar to those for benzodiazepines and gabapentin, with quetiapine-specific adjustments.

    Slow taper. Reductions of 12.5 to 25 mg every two to four weeks, with smaller reductions as the dose falls below 25 mg, are well tolerated by most patients. For patients on long-term use or with prior failed attempts, slower is better. The Maudsley Deprescribing Guidelines (Horowitz and Taylor, 2024) provide hyperbolic tapering schedules for antipsychotics, including quetiapine, that are applicable here.

    Liquid formulation at low doses. Quetiapine is available as a suspension for compounding; small, smooth reductions below 25 mg are not feasible with tablets.

    Non-pharmacologic sleep work in parallel. The taper is easier if basic sleep hygiene, stimulus-control therapy, and a stable schedule are in place before the first reduction. Cognitive behavioral therapy for insomnia (CBT-I) is the evidence-based treatment for chronic insomnia and has durable effects that the medications do not produce.

    Hold through rebound. A rebound flare during dose reduction is not a signal to restart; it is a signal to hold the dose for another two to four weeks before the next reduction.

    What to Ask at the Prescriber Visit

    Patients on quetiapine for sleep can reasonably raise several questions: What is the off-label evidence for quetiapine in insomnia? What is the plan for eventual discontinuation? What metabolic monitoring has been done? Are there alternative approaches — CBT-I, sleep restriction therapy — that have not yet been tried?

    These are not adversarial questions. They are the questions that ought to be answered at the time a low-dose antipsychotic is being considered for an off-label sleep indication. When they are answered, the prescription is often still appropriate. When they are not answered and the prescription is written anyway, the pattern is the one this post describes.

  • Gabapentin Dependence: The Overlooked Deprescribing Challenge

    Gabapentin Dependence: The Overlooked Deprescribing Challenge

    Gabapentin is prescribed for an expanding list of conditions: neuropathic pain, partial seizures, fibromyalgia, restless legs, anxiety, insomnia, alcohol withdrawal, and opioid-sparing postoperative analgesia. The prescribing profile has grown considerably faster than the evidence base, and the drug’s reputation as a benign, non-controlled alternative to benzodiazepines and opioids has produced a cohort of patients who are physically dependent on gabapentin with little recognition of that fact by their prescribers.

    The word “dependence” here is narrow. Gabapentin has modest abuse potential — particularly in polysubstance users, particularly at supratherapeutic doses — but that is not the common clinical problem. The common problem is iatrogenic physical dependence in patients taking prescribed doses, who cannot stop the medication without significant withdrawal symptoms and who are rarely warned that this is possible.

    Pharmacology, Briefly

    Despite its name, gabapentin does not act directly on GABA-A receptors. It binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing presynaptic calcium influx and attenuating excitatory neurotransmitter release — particularly glutamate, but also norepinephrine and substance P. This mechanism underlies its analgesic, anxiolytic, and anticonvulsant effects. The relevance to dependence is that chronic suppression of calcium channel function produces compensatory adaptations; when the drug is removed, the channel activity rebounds, producing a state that clinically resembles benzodiazepine withdrawal in many features.

    Recognizing Physical Dependence

    Physical dependence on gabapentin emerges on a predictable timescale — usually weeks to a few months of consistent dosing. Patients do not typically describe it as dependence; they describe the following.

    Rebound symptoms when a dose is missed or delayed. Anxiety, irritability, insomnia, headache, or return of the original pain complaint within 12 to 24 hours of a missed dose.

    Dose-inflexibility. Attempts to lower the dose produce symptoms that the patient interprets as return of the underlying condition, leading back to the original dose.

    New symptoms on stable dose. Some patients develop a syndrome that resembles tolerance: anxiety, insomnia, restless sensations, or cognitive symptoms that were not present at baseline and are incompletely relieved by the next dose.

    The Withdrawal Syndrome

    Acute gabapentin withdrawal in a physically dependent patient can include anxiety, insomnia, tremor, sweating, nausea, headache, palpitations, and restlessness. Reports of withdrawal seizures exist, particularly after abrupt discontinuation of high-dose regimens. In patients with histories of benzodiazepine exposure or other GABA-system involvement, the withdrawal picture can be indistinguishable from benzodiazepine withdrawal, which makes separating cause and contribution difficult when the two medications are being tapered simultaneously.

    A protracted course has been described but is less well characterized than in benzodiazepines. Some patients report months of residual symptoms after discontinuation, including heightened sensory sensitivity and autonomic features.

    Why Deprescribing Is Overlooked

    Several structural factors contribute.

    The first is the prescribing context. Gabapentin is often added opportunistically — to manage pain during a benzodiazepine taper, to address insomnia from SSRI withdrawal, to provide an opioid-sparing adjunct after surgery — with no exit strategy defined. The initial prescription tends to become the chronic prescription.

    The second is the drug’s low-profile reputation. Because gabapentin is not federally scheduled (it is controlled in some states; pregabalin carries Schedule V status federally), prescribers treat it as low risk and rarely initiate a deprescribing conversation.

    The third is diagnostic confusion. When a patient’s attempt to reduce gabapentin produces anxiety and insomnia, the default interpretation is that the original indication has returned and requires continued treatment. The withdrawal framework is often not considered.

    How to Approach Deprescribing

    The principles parallel what the Ashton Manual and Maudsley Deprescribing Guidelines (Horowitz and Taylor, 2024) recommend for benzodiazepines, with some adjustments specific to gabapentin pharmacology.

    Slow taper. Reductions of 10% per month from current dose, with smaller reductions as the dose falls, are well tolerated by most patients. Faster protocols sometimes work in short-exposure patients; slower protocols are needed for patients with years of use or concurrent benzodiazepine exposure.

    Dose redistribution before reduction. For patients on twice-daily dosing, shifting to three-times-daily dosing before starting reductions can reduce interdose symptoms and make subsequent reductions more tolerable.

    Liquid or compounded formulations at lower doses. Once the dose is below 300 mg daily, tablet strengths limit precision, and a compounded liquid allows smooth reductions.

    Parallel tapers with caution. If a patient is tapering both a benzodiazepine and gabapentin, the usual recommendation is to taper one at a time rather than both simultaneously. Which to do first depends on the clinical picture and the symptoms driving the decision, but running both tapers in parallel multiplies the withdrawal burden in a way most patients cannot sustain.

    Hold through flares. Dose holds during symptom exacerbations work in the same way they do for benzodiazepines — buying time for the nervous system to adapt before the next reduction.

    Gabapentin Added During a Benzodiazepine Taper

    A specific clinical question is whether gabapentin should be added during a benzodiazepine taper to manage withdrawal symptoms. The short answer is: rarely, and not without a deprescribing plan defined before the first dose is given.

    Adding gabapentin to a benzodiazepine taper can produce short-term symptom relief. It also produces a new dependence with its own withdrawal course, and the patient then faces two tapers instead of one. For some patients — particularly those with intractable neuropathic pain or seizure disorders — the trade-off may still be favorable. For most, it is not.

    Patients who find themselves on gabapentin that was added during a prior benzodiazepine taper, and who are now facing the gabapentin taper as a second problem, are a recognizable clinical population. The solution is not to accelerate either taper but to complete them sequentially, with adequate time for stabilization between.

    What to Ask For

    Patients who suspect they may be physically dependent on gabapentin can raise the question directly with their prescriber. Useful framings: “I’d like to understand what happens if I stop this medication,” “what is the deprescribing plan,” and “what would a slow taper look like.” The absence of a clear answer to these questions is itself useful information.

    Gabapentin dependence is a clinical reality that the current prescribing culture around the drug does not reliably recognize. Addressing it requires treating gabapentin with the same care that benzodiazepines are increasingly receiving — which is to say, acknowledging that long-term use produces adaptations, and that removal requires planning.

  • Kindling and Benzodiazepines: Why Failed Tapers Make the Next One Harder

    Kindling and Benzodiazepines: Why Failed Tapers Make the Next One Harder

    Kindling, in the addiction and withdrawal literature, refers to the phenomenon in which repeated cycles of withdrawal produce progressively worse withdrawal syndromes on each subsequent cycle. The mechanism was first characterized in alcohol dependence by Robert Post and others in the 1980s, where the observation was clinical and unambiguous: patients with histories of multiple detoxifications from alcohol had more severe, more medication-resistant, and more seizure-prone withdrawal courses than patients undergoing a first detox. The same framework, with stronger and weaker evidence depending on the specific claim, has been extended to benzodiazepines.

    For patients who have attempted and failed one or more benzodiazepine tapers, this matters. Each failed attempt may not be a neutral event; the preliminary evidence suggests that the next attempt is starting from a harder place than the first.

    What Kindling Actually Describes

    Two overlapping phenomena are usually bundled under the term.

    The first is neuronal sensitization. Repeated withdrawal episodes produce lasting changes in excitatory and inhibitory neurotransmission that lower the threshold for symptom emergence and seizure on subsequent withdrawals. The word “kindling” is borrowed from the experimental model in which repeated subthreshold electrical stimulation of the amygdala eventually produces spontaneous seizures at intensities that were originally subthreshold. The withdrawal application extends this: repeated subthreshold excitatory episodes — withdrawal-induced hyperexcitability — produce durable changes in the circuitry’s response to subsequent insults.

    The second is behavioral or affective sensitization. Each withdrawal episode produces more severe subjective symptoms than the last, independent of any measurable seizure threshold. Patients report that a second or third attempt at a taper is “not just the first withdrawal again” but is qualitatively more intense, more protracted, and more refractory to standard symptom management.

    The Evidence in Benzodiazepines

    The kindling literature in benzodiazepines is not as robust as in alcohol, but several lines of evidence converge.

    Animal work demonstrates that repeated withdrawal from chronic benzodiazepine administration produces increasing signs of withdrawal severity and, in some paradigms, reductions in GABA-A receptor function beyond what single-cycle withdrawal produces.

    Clinical observation, accumulated across decades of case series and the Ashton Manual’s patient cohorts, describes a recognizable pattern in which patients who have attempted rapid detox, or who have cycled off and back on benzodiazepines multiple times, present with withdrawal courses that are unusually severe and prolonged relative to their total benzodiazepine exposure.

    The overlap with patients who later develop features consistent with benzodiazepine-induced neurological dysfunction (BIND) is notable. Ritvo and colleagues’ 2023 description of BIND includes multiple withdrawal attempts as a feature in a meaningful proportion of the reported cohort.

    The mechanism is not fully characterized. Candidates include glutamatergic upregulation, persistent alterations in GABA-A receptor subunit composition, secondary neuroinflammation, and HPA axis changes. Whichever mechanism or combination is operative, the clinical implication is the same: the safest number of taper attempts is one successful one.

    What This Means for Taper Strategy

    The priority when a patient has a history of one or more failed tapers is not simply to “try again with more conviction.” Three considerations follow from the kindling framework.

    First, pace should be even slower than standard. If a taper at 5% per month was intolerable last time, restarting at 5% per month is not a reasonable plan. Starting at 2.5% or lower, with hyperbolic reductions that decrease as the dose falls, is the pattern most consistent with the Maudsley Deprescribing Guidelines’ approach to patients with complicated histories.

    Second, stabilization before reduction is not a sign of failure. Patients who have kindled often need weeks to months at a stable dose before they can tolerate any further reduction. This is not time wasted; it is time during which the nervous system is not being re-provoked into another withdrawal episode. A taper that does not move for two months in a kindled patient is a better outcome than a taper that moves quickly and fails again.

    Third, the temptation to abandon a slow taper for a faster alternative is particularly dangerous in this population. The patient who has already failed one rapid detox is the patient whose next rapid detox is most likely to produce severe protracted harm. The arithmetic does not improve with repetition.

    Managing a Kindled Patient

    Several practical principles apply.

    Switch to a longer-acting agent if feasible. Interdose withdrawal on short-acting benzodiazepines is itself a form of micro-withdrawal and, in a kindled patient, should be minimized. A carefully executed Ashton-style substitution to diazepam can stabilize the interdose period before tapering resumes. The Maudsley Deprescribing Guidelines offer refined substitution ratios and a more cautious approach for complex cases.

    Use liquid or compounded formulations when the dose becomes too low for commercially available tablet fractions. Precision matters more in kindled patients; a 12.5% dose reduction is different from a 10% reduction at these dose levels, and approximate cutting produces approximate results.

    Hold the dose through exacerbations. A kindled patient in a symptom flare who reduces dose anyway is likely to worsen. Holding — sometimes for weeks — is usually the correct move.

    Coordinate with a clinician who will not push. The single most common path to repeated kindling is a prescriber who interprets the patient’s reasonable request to slow down as non-adherence and continues to move the dose anyway. A collaborative taper is a kindling-reducing intervention in itself.

    A Note on Patients Who Have Already Kindled

    Patients in this category often arrive having been told that their severe symptoms on prior attempts were psychosomatic, psychiatric, or reflective of underlying personality features. The kindling framework reframes the same clinical observation in neurobiological terms. This is not a minor point for the patient’s treatment or their engagement with a subsequent attempt; a patient who believes their problem is their psychology is harder to taper than a patient who understands they are managing a sensitized nervous system.

    The pattern of failed tapers making subsequent tapers harder is real, and it is the single strongest argument for getting the first attempt right. For patients who are past that point, the work now is to approach the next attempt with enough caution to keep it from becoming another data point in the kindling series.

  • Why Rapid Benzo Detox Programs Fail

    Why Rapid Benzo Detox Programs Fail

    Rapid benzodiazepine detoxification programs — inpatient protocols that promise discontinuation from a long-term benzodiazepine prescription in three to seven days, often with flumazenil infusion or heavy sedation — are advertised aggressively to patients who are miserable, desperate, and frequently dismissed by their regular prescribers. They fill a real void. They also routinely produce the exact outcome they promise to avoid: prolonged, severe withdrawal that can persist long after discharge and, in some cases, evolve into benzodiazepine-induced neurological dysfunction (BIND), the protracted syndrome described by Ritvo and colleagues in 2023.

    The core problem is a category error. Detox is a meaningful intervention for substances with predictable, self-limited withdrawal courses — alcohol and opioids being the primary examples. Benzodiazepine physiology is not in that category, and treating it as if it were is the pharmacologic source of the harm.

    How Rapid Detox Programs Are Structured

    Models vary, but the common format is brief inpatient admission (typically three to seven days) during which the patient’s benzodiazepine is stopped abruptly. Symptom control is attempted with adjuncts: clonidine, gabapentin, antiemetics, propofol or other sedatives, and in some programs flumazenil infusion. Flumazenil, a benzodiazepine receptor antagonist, is positioned in marketing material as a mechanism to “reset” receptor function. It is an FDA-approved agent for benzodiazepine overdose reversal; its use in detox is off-label, with limited evidence and a known risk of seizures.

    Programs frequently emphasize rapid return to normal function and discharge with minimal medication. What the discharge summary does not usually convey is that benzodiazepine withdrawal has a course measured in months, not days, and that acute symptom suppression during an inpatient stay has very little bearing on what happens three, six, or twelve weeks later.

    Why the Pharmacology Does Not Support It

    Long-term benzodiazepine exposure produces adaptations at the GABA-A receptor complex: downregulation, subunit composition shifts, and altered sensitivity. These changes take weeks to months to reverse, and the trajectory is not linear. Abrupt cessation unmasks the adaptation without any compensatory mechanism to absorb it, producing a state of GABAergic insufficiency in a nervous system that has been operating with external GABA amplification for sometimes years. Seizure risk is the most visible acute consequence; the less visible and more common outcome is a withdrawal course that extends far beyond the inpatient stay.

    Kindling is the second pharmacologic concern. Repeated cycles of benzodiazepine withdrawal — a first failed detox, resumption, another attempt — appear to lower the threshold for severe withdrawal on each subsequent attempt. Patients who have failed one rapid detox are often harder to taper successfully than patients who have never attempted one, and the rapid detox model almost guarantees a failed attempt.

    The Ashton Manual, first published by Professor C. Heather Ashton in 1999 and revised in 2002, lays out the alternative that every subsequent evidence-based framework — including the Maudsley Deprescribing Guidelines (Horowitz and Taylor, 2024) — has reaffirmed: slow, individualized dose reduction over months, with the pace set by the patient’s symptoms rather than by a fixed schedule. The Maudsley framework formalizes hyperbolic tapering: reductions that get proportionally smaller as the dose gets lower, reflecting the non-linear relationship between dose and GABA-A receptor occupancy.

    What the Evidence Looks Like

    There are no randomized trials supporting rapid detox as superior to gradual tapering for long-term benzodiazepine users. The published literature on flumazenil infusion consists primarily of case series and open-label studies, generally without follow-up long enough to detect protracted withdrawal or BIND. By contrast, the evidence for slow, patient-paced tapering is accumulated across decades of clinical experience documented in the Ashton Manual, the work of the Benzodiazepine Information Coalition, multiple published guidelines, and the recent formalization of hyperbolic tapering in the Maudsley guidelines.

    The absence of a rigorous evidence base for rapid detox is itself informative. Were these programs producing sustained remission at rates competitive with gradual tapering, the trials would exist. The programs continue to operate because they fill a demand, not because they survive clinical scrutiny.

    What Patients End Up With

    The clinical presentation after a failed rapid detox is recognizable. Patients arrive in protracted withdrawal weeks to months after discharge — sometimes reinstated on benzodiazepines at lower doses, sometimes not — with intensified symptoms, sleep architecture damage, sensory hypersensitivity, autonomic instability, and a course that now requires substantially more careful management than would have been needed had a slow taper been offered in the first place. A meaningful subset develop features consistent with BIND and face recovery timelines of a year or more.

    The economic picture compounds the clinical one. Rapid detox programs are typically not covered by insurance, and out-of-pocket costs can reach tens of thousands of dollars. Patients who have paid for an unsuccessful detox often have limited resources for the subsequent care that the failed detox makes necessary.

    The Evidence-Based Alternative

    Patients considering a rapid detox program are best served by a different approach: a careful, individualized, hyperbolic taper conducted with a clinician willing to set the pace by symptom tolerance rather than calendar. For patients whose current prescribers will not provide this, options include seeking out clinicians who specifically work with benzodiazepine tapering, requesting a liquid or compounded formulation to permit fine dose adjustments, and using the Ashton Manual and Maudsley Deprescribing Guidelines as reference documents in visits.

    This takes longer. It is also the approach with the evidence behind it.

    A Practical Caveat

    None of the above is an argument against inpatient care in selected situations. Patients with active suicidal ideation, intractable seizures, unstable comorbid illness, or safety concerns at home can benefit from hospitalization during a taper. But the taper still needs to be a taper. Hospitalizing a patient to enable a slow, monitored reduction is a different intervention from hospitalizing them to enable a rapid discontinuation. The first is good care. The second is the pattern that produces most of the cases clinicians familiar with BIND end up treating.